- Oral presentation
- Open Access
European Cardiovascular Magnetic Resonance (EuroCMR) registry - multi national tesults from 57 centers in 15 countries
© Wagner et al; licensee BioMed Central Ltd. 2013
- Published: 30 January 2013
- Cardiovascular Magnetic Resonance
- Interim Analysis
- Hypertrophic Cardiomyopathy
- Suspected Coronary Artery Disease
The EuroCMR registry determined indications, image quality, safety and impact on patient management of clinical routine CMR in a multi-national European setting.
Furthermore, interim analyses of two specific protocols evaluating the prognostic potential of CMR in patients with coronary artery disease (CAD) and hypertrophic cardiomyopathy (HCM) are presented.
Multi-center registry with consecutive enrollment of patients in 57 centers in 15 countries .
27,781 patients were enrolled. The most frequent indications were risk stratification in CAD/ischemia (34.2%), workup of cardiomyopathies (32.2%) and assessment of viability (14.6%). Image quality was diagnostic in 98%. Severe complications were rare (0.03%).
Impact of CMR on patient management by indication
All (from n = 27781)
Change in medication
Impact on patient management (new diagnosis and/or therapeutic consequence)
Kaplan-Meier survival curves of the interim analyses showed low adverse event rates in patients with suspected CAD with a normal stress CMR (1.0% per year), and in HCM without delayed enhancement (2.7% per year).
The most important CMR indications in Europe are risk stratification in suspected CAD/ischemia, work-up of cardiomyopathies and assessment of viability. CMR is a safe procedure, has diagnostic image quality in more than 98% of cases, and its results have a strong impact on patient management. Interim analyses underscore the prognostic value of clinical routine CMR in patients with CAD and HCM.
Medtronic Inc., Minneapolis MN, USA.
Novartis International AG, Basel, Switzerland.
Siemens Health Care, Erlangen, Germany.
- Wagner A: . J Cardiovasc Magn Resn. 2009Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.